聯(lián)系我們時請說明是91化工儀器網(wǎng)上看到的信息，謝謝!

產(chǎn)品簡介 品牌 MedChemExpress (MCE) 貨號 HY-15247 規(guī)格 10 mM * 1 mL；2 mg；5 mg；10 mg；50 mg；100 m 供貨周期 現(xiàn)貨 應用領域 生物產(chǎn)業(yè)     Vistusertib （AZD2014） 是一種ATP競爭性的 mTOR 抑制劑，IC50 為 2.81 nM。AZD2014 抑制 mTORC1 和 mTORC2 復合物。
詳細介紹 Vistusertib

產(chǎn)品活性：Vistusertib (AZD2014) 是一種ATP競爭性的 mTOR 抑制劑，IC50 為 2.81 nM。AZD2014 抑制 mTORC1 和 mTORC2 復合物。

研究領域：PI3K/Akt/mTOR | Autophagy

作用靶點：mTOR | Autophagy

In Vitro: The inhibitory effects of Vistusertib (AZD2014) are measured against isolated recombinant mTOR enzyme (IC50 of 2.81 nM) as well as in cellular assays measuring both mTORC1 and mTORC2 activities. In MDAMB468 cells, Vistusertib (AZD2014) decreases the phosphorylation of the mTORC1 substrate ribosomal protein S6 (Ser235/236) with a mean IC50 value of 210 nM and the mTORC2 substrate AKT (Ser473) with a mean IC50 value of 78 nM.

In Vivo: Vistusertib (AZD2014) induces dose-dependent tumor growth inhibition in several xenograft and primary explant models. The antitumor activity of Vistusertib (AZD2014) is associated with modulation of both mTORC1 and mTORC2 substrates, consistent with its mechanism of action. The pharmacokinetics of Vistusertib (AZD2014) in mice is tested upon administration of doses between 7.5 and 15 mg/kg. A dose-dependent increase in Cmax and AUC is observed following single dose and repeat dosing of AZD2014: Cmax range from 1 to 16 μM and AUC range from 220 to 5,042 μM·h across this dose range. The pharmacodynamic effect of Vistusertib (AZD2014) against an mTORC1 biomarker (phosphorylation of S6) and an mTORC2 biomarker (phosphorylation of AKT) is assessed in SCID mice bearing MCF7 xenografts following administration of 3.75, 7.5, and 15 mg/kg AZD2014. There is a good relationship between the drug plasma concentrations and biomarker levels (estimated p-AKT IC50 of 0.119 μM total, 53% SE, and estimated p-S6 IC50 0.392 μM, 28.8% SE).

相關產(chǎn)品：Drug Repurposing Compound Library | Anti-Aging Compound Library | Kinase Inhibitor Library | Clinical Compound Library | Clinical Compound Library Plus | PI3K/Akt/mTOR Compound Library | Anti-Cancer Compound Library | Drug Repurposing Compound Library Plus | Bioactive Compound Library Plus | Autophagy Compound Library | Rapamycin | Everolimus | Torin 1 | MHY1485 | AZD-8055 | Sapanisertib | Dactolisib | LY3023414 | Temsirolimus | Torin 2 | Torkinib | Salidroside | PF-04691502 | Omipalisib | PI-103 | Bimiralisib | OSI-027 | Dihydromyricetin | 3BDO | Gedatolisib | Apitolisib | Voxtalisib | KU-0063794 | Deforolimus | CC-115 | GDC-0084 | PP121 | CC-223

以上信息由企業(yè)自行提供，信息內(nèi)容的真實性、準確性和合法性由相關企業(yè)負責，91化工儀器網(wǎng)對此不承擔任何保證責任。
溫馨提示：為規(guī)避購買風險，建議您在購買產(chǎn)品前務必確認供應商資質(zhì)及產(chǎn)品質(zhì)量。 搜本商鋪 或 搜全站

MedChemExpress LLC - 主營產(chǎn)品： 西羅莫司 Rapamycin,瑞沙托維 TAK-242,奧拉帕尼 Olaparib

地址：上海市浦東新區(qū)張衡路1999弄3號樓      聯(lián)系電話：86-021-58955995      手機：18019480960     傳真：86-021-53700325
91化工儀器網(wǎng) 設計制作，未經(jīng)允許翻錄必究 .      Copyright(C) http://www.chem17.com,      All rights reserved. 以上信息由企業(yè)自行提供，信息內(nèi)容的真實性、準確性和合法性由相關企業(yè)負責，91化工儀器網(wǎng)對此不承擔任何保證責任。
溫馨提示：為規(guī)避購買風險，建議您在購買產(chǎn)品前務必確認供應商資質(zhì)及產(chǎn)品質(zhì)量。
會員登錄